Best treatment plan for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial is for people with T4 esophageal cancer, where the tumor has spread to nearby organs. It aims to find the best treatment approach to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed type of esophageal cancer called squamous cell carcinoma.
- Your cancer must have spread to nearby organs (T4 stage).
- You are between 18 and 70 years old.
- You must be in generally good health (able to take care of yourself).
- Your blood counts, liver function, and kidney function must be within certain safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
This trial tests a combination of a new form of chemotherapy (docetaxel albumin-bound), an immunotherapy (SG001), and standard chemotherapy (cisplatin) plus radiation for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This study tests whether adding tislelizumab to chemotherapy or radiation can work better for older adults with advanced or recurrent/metastatic esophageal squamous cell cancer. The goal is to slow the cancer down and improve control of the disease.
Hear when a new Esophageal Cancer TNM Staging Primary Tumor (T) T4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.